colorectal-cancer

A simple blood test before surgery predicts which colorectal liver cancer patients will relapse fast.

Pretreatment ctDNA (circulating tumor DNA) levels measured by affordable mFast-SeqS sequencing classified 19% of 182 colorectal liver metastasis patients as ctDNA-high. These patients had 1-year RFS of 29% vs. 52% and 3-year OS of 48% vs. 78% compared to ctDNA-low patients, and were at higher risk…

Dan Manning

Dan Manning

— 1 min read
Share
A simple blood test before surgery predicts which colorectal liver cancer patients will relapse fast.

A simple blood test before surgery predicts which colorectal liver cancer patients will relapse fast.

Pretreatment ctDNA (circulating tumor DNA) levels measured by affordable mFast-SeqS sequencing classified 19% of 182 colorectal liver metastasis patients as ctDNA-high. These patients had 1-year RFS of 29% vs. 52% and 3-year OS of 48% vs. 78% compared to ctDNA-low patients, and were at higher risk for multiorgan recurrence.

This minimally invasive test could improve pre-surgical risk stratification for this patient population.

Key Findings

  • 19% of CRLM patients classified ctDNA-high by mFast-SeqS
  • ctDNA-high: 1-year RFS 29% vs. 52%; 3-year OS 48% vs. 78%
  • High ctDNA associated with multiorgan recurrence
  • mFast-SeqS is affordable and minimally invasive

Implications

Preoperative ctDNA testing could stratify patients for intensified adjuvant therapy or clinical trial enrollment.

Caveats

Retrospective study (n=182); abstract-only. Prospective multicenter validation required.

Source: The British journal of surgery — 2026-04-09

Read more